VTP50469

• Description :

  VTP50469 is a potent, highly selective and orally active Menin-MLL interaction inhibitor with a Ki of 104 pM. VTP50469 has potently anti-leukemia activity[1][2].

• Product Name Alternative :

  GCA-1

• UNSPSC :

  12352005

• Target :

  Apoptosis; Epigenetic Reader Domain

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Epigenetics

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/vtp50469.html

• Purity :

  99.69

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(N(C(C)C)C(C)C)C1=CC(F)=CC=C1OC2=CN=CN=C2N3CC4(CCN(C[C@H]5CC[C@H](NS(=O)(C)=O)CC5)CC4)C3

• Molecular Formula :

  C32H47FN6O4S

• Molecular Weight :

  630.82

• References & Citations :

  [1]Krivtsov AV, et al. A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. Cancer Cell. 2019 Dec 9;36 (6) :660-673.e11.|[2]Andrei V. Krivtsov, et al. Abstract 4958: VTP50469 is a novel, orally available menin-MLL1 inhibitor effective against MLL-rearranged and NPM1-mutant leukemia. Cancer Resceach. July 2018.Volume 78, Issue 13 Supplement.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2169916-18-9]